Cargando…

Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease

BACKGROUND & AIMS: There is great current interest in the potential application of DNA methylation alterations in peripheral blood leukocytes (PBLs) as biomarkers of susceptibility, progression, and treatment response in inflammatory bowel disease (IBD). However, the intra-individual stability o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joustra, Vincent, Li Yim, Andrew Y.F., Hageman, Ishtu, Levin, Evgeni, Adams, Alex, Satsangi, Jack, de Jonge, Wouter J., Henneman, Peter, D’Haens, Geert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972576/ https://www.ncbi.nlm.nih.gov/pubmed/36581079 http://dx.doi.org/10.1016/j.jcmgh.2022.12.011

Ejemplares similares

Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Peripheral Blood DNA Methylation Profiles Do Not Predict Endoscopic Post-Operative Recurrence in Crohn’s Disease Patients
por: Joustra, Vincent W., et al.
Publicado: (2022)

Peripheral blood methylation profiling of female Crohn’s disease patients
por: Li Yim, Andrew Y. F., et al.
Publicado: (2016)

Whole-Genome DNA Methylation Profiling of CD14+ Monocytes Reveals Disease Status and Activity Differences in Crohn’s Disease Patients
por: Li Yim, Andrew Y.F., et al.
Publicado: (2020)

Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis
por: de Krijger, Manon, et al.
Publicado: (2022)

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
por: Elfiky, Ahmed M. I., et al.
Publicado: (2022)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
por: Colombel, Jean-Frédéric, et al.
Publicado: (2020)

SARS-CoV-2 vaccination for patients with inflammatory bowel disease
por: Garrido, Hannah M Garcia, et al.
Publicado: (2021)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease
por: De Voogd, Floris, et al.
Publicado: (2021)

Natural History and Risk Stratification of Recurrent Crohn’s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study
por: Joustra, Vincent, et al.
Publicado: (2021)

A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn’s disease patients
por: Li Yim, Andrew Y. F., et al.
Publicado: (2018)

The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease
por: Nikolakis, Dimitrios, et al.
Publicado: (2022)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress
por: van Wassenaer, Elsa A, et al.
Publicado: (2021)

Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
por: Volkers, Adriaan, et al.
Publicado: (2023)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Marquès Camí, Miquel, et al.
Publicado: (2021)

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
por: Berends, Sophie E., et al.
Publicado: (2019)

Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial
por: Hoekman, Daniël R, et al.
Publicado: (2020)

Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic
por: Brain, Oliver, et al.
Publicado: (2021)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms
por: Frigerio, Sofía, et al.
Publicado: (2021)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease
por: Elfiky, Ahmed M I, et al.
Publicado: (2021)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

Impaired Quality of Working Life in Inflammatory Bowel Disease Patients
por: van Gennep, Sara, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy
por: Selim, Rania, et al.
Publicado: (2022)

Effects of fecal microbiota transplant on DNA methylation in subjects with metabolic syndrome
por: van der Vossen, Eduard W. J., et al.
Publicado: (2021)

Dysregulation of Human β-Defensin-2 Protein in Inflammatory Bowel Disease
por: Aldhous, Marian C., et al.
Publicado: (2009)

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease
por: Wellens, Judith, et al.
Publicado: (2022)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9barh6k54db7c0a0i3u7e78bb2